IDEXX LABORATORIES INC /DE — Director's Dealing 2017

May 11, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2017-05-10

Reporting Person: AYERS JONATHAN W (Director, Chairman, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-05-10	Common Stock	M	10000	$38.7950	Acquired	1024994	Direct
2017-05-10	Common Stock	S	10000	$162.3092	Disposed	1014994	Direct
2017-05-10	Common Stock	M	20000	$38.7950	Acquired	1034994	Direct
2017-05-10	Common Stock	S	6200	$162.2830	Disposed	1028794	Direct
2017-05-10	Common Stock	S	10800	$163.2760	Disposed	1014994	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-10	Non-Qualified Stock Option (right-to-buy)	$38.7950	M	10000	Disposed	2018-02-13	Common Stock (10000)	Direct
2017-05-10	Non-Qualified Stock Option (right-to-buy)	$38.7950	M	20000	Disposed	2018-02-13	Common Stock (20000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	98000	Indirect

Footnotes

F1: Represents the weighted average sales price of the shares sold ranging from a low of $161.55 to a high of $162.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F2: Represents the weighted average sales price of the shares sold ranging from a low of $161.95 to a high of $162.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: Represents the weighted average sales price of the shares sold ranging from a low of $163.04 to a high of $163.60 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F5: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F6: Not applicable.